glp 1 agonist anesthesia Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists Exploring the Side Effects of
Description
E., Barnes D
Intraperitoneal injections having doses of 1015 mg/kg/day for two weeks in people exhibit features analogous to those observed in animal models [31]
Fast withdrawals matter, but so do predictable timeframes and transparent identity checks
In alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial
Availability of data and materials Not applicable
